ALGN · NMS · Healthcare
Align Technology, Inc.
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 78.08
Market price
USD 147.61
Implied upside
-47.1%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 4.1bn | USD 4.2bn | USD 4.4bn | USD 4.5bn | USD 4.6bn | +2.6% |
| EBIT | USD 681.3m | USD 699.1m | USD 717.3m | USD 736.1m | USD 755.3m | +2.6% |
| NOPAT | USD 538.2m | USD 552.3m | USD 566.7m | USD 581.5m | USD 596.7m | +2.6% |
| Add depreciation & amortisation | USD 171.5m | USD 176.0m | USD 180.6m | USD 185.3m | USD 190.1m | +2.6% |
| Less capital expenditure | USD -184.7m | USD -189.6m | USD -194.5m | USD -199.6m | USD -204.8m | +2.6% |
| Less increase in working capital | USD -55.8m | USD -57.3m | USD -58.8m | USD -60.3m | USD -61.9m | +2.6% |
| Free cashflow to firm | USD 469.1m | USD 481.4m | USD 494.0m | USD 506.9m | USD 520.1m | +2.6% |
| Discount factor | 0.9416 | 0.8348 | 0.7402 | 0.6563 | 0.5819 | - |
| Present value | USD 441.8m | USD 401.9m | USD 365.6m | USD 332.6m | USD 302.6m | -9.0% |
| Present Value Of The Forecast | USD 1.8bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.00% | US 10-year Treasury (^TNX) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 1.431 | Reported 1.643, pulled toward 1.0 (Blume) |
| Cost of equity | 12.87% | Risk-free + beta x equity risk premium |
| Cost of debt | 7.00% | Assumed: risk-free + 2bp (interest expense not reported) |
| Market capitalisation | USD 10.5bn | 98.9% of capital |
| Total debt | USD 114.4m | 1.1% of capital, book value as a proxy |
| Tax rate | 21.0% | Effective, capped at statutory |
| WACC | 12.79% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
61% of EV
- Forecast FCFF, final year
- USD 520.1m
- Capex at depreciation, working capital in reinvestment
- USD 596.7m
- Less reinvestment at g/ROIC (17.8% of NOPAT)
- USD -106.3m
- Capitalised
- USD 490.4m
- ROIC (reported)
- 14.0%
- Terminal value, undiscounted
- USD 4.9bn
- Terminal value, discounted
- USD 2.8bn
- Enterprise value
- USD 4.7bn
- Less net debt
- USD -980.5m
- Equity value
- USD 5.7bn
Exit at 11.6x EBITDA
78% of EV
- Terminal value, undiscounted
- USD 10.9bn
- Terminal value, discounted
- USD 6.4bn
- Enterprise value
- USD 8.2bn
- Less net debt
- USD -980.5m
- Equity value
- USD 9.2bn
Spread between methods: 47%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 10.79% | 90.59 | 91.59 | 92.69 | 93.90 | 95.26 |
| 11.79% | 83.32 | 83.93 | 84.60 | 85.32 | 86.11 |
| 12.79% | 77.33 | 77.69 | 78.08 | 78.49 | 78.92 |
| 13.79% | 72.32 | 72.51 | 72.71 | 72.91 | 73.12 |
| 14.79% | 68.25 | 68.39 | 68.54 | 68.69 | 68.84 |
Outlined: this model. Green text: above today's price of 147.61. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 2.6% | 31.2% | +28.6pp |
| EBIT margin | 16.5% | 33.2% | +16.7pp |
| Discount rate | 12.8% | 7.3% | -5.5pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.